摘要 |
The prevent invention provides the use of a combination of an anti-human interleukin-6 monoclonal antibody (IL-6A) and an anti-human IL-6 receptor monoclonal antibody (IL-6RA) as effective components: (1) in the treatment of tumours produce Interleukin-10 which is induced by Interleukin-6, (2) in the treatment of multiple myeloma (plasmozytoma) produces Interleukin-10 which is induced by Interleukin-6 and (3) in the treatment of Interleukin-6 dependent tumours. Interleukin-10 leads to an enhanced proliferation of tumour cells. |